Trials / NCT03326336
Dose-escalation Study to Evaluate the Safety and Tolerability of GS030 in Subjects With Retinitis Pigmentosa
Underway, not enrolling Phase 1 / Phase 2 Optogenetics, Gene therapy
- Sponsor
- GenSight Biologics
- Treatment
- Gene therapy: GS030-DP AND Medical device: GS030-MD
- Gene
- Not gene-specific
- Conditions
- Non-syndromic Retinitis Pigmentosa
- Ages
- 18 Years to 75 Years
- Enrollment
- 10 participants
- Started
- 2018-09-26
- Main results expected
- 2027-10-26
- Results posted
- Not yet
- Record last updated
- 2026-03-02
What the study is testing
The objective of this study is to evaluate the safety and tolerability of escalating doses of a gene therapy called GS030-DP (injected study treatment) administered via a single intravitreal injection and repeated light stimulation using a medical device called GS030-MD (stimulating glasses) in subjects with documented diagnosis of non-syndromic Retinitis Pigmentosa
Where it runs
France (1)
- Centre Hospitalier National d'Ophtalmologie (CHNP) des Quinze-Vingts, Paris
United Kingdom (1)
- Moorfields Eye Hospital NHS Foundation Trust, 162 City Road, London
United States (1)
- UPMC Eye Center, Pittsburgh, Pennsylvania